Technology Offerings

New Combretastatin Analogs – chemotherapeutic agents against multidrug resistant cancer

Vascular disrupting agents (VDA) can overcome the multidrug resistance of tumors by targeting specifically tumor vasculature. The present invention relates to specific analogs of combretastatin in the treatment or prevention of cancer, including multidrug-resistant and combretastatin-refractory cancers.

Developmental Status: Pharmacodynamical and toxicological studies currently in the works , Animal data available, Further mouse studies on tumor xenografts from other entities planned, Compound samples available for testing

Further information: PDF

Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0

Contact
Peer Biskup

As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.

Comments (0)

Write a comment